APA
(20140521). A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From AASLD 2012: The 63rd Annual Meeting of the American Association for the Study of Liver DiseasesNovember 9-13, 2012 • Boston, MassachusettsSpecial Reporting on:• Timing and Magnitude of Ribavirin Dose Reduction Do Not Impact SVR Rates with Boceprevir Plus Peginterferon α and Ribavirin• A 12-Week Interferon-Free Treatment Regimen with ABT-450/r, ABT-267, ABT-333, and Ribavirin Achieves High SVR12 Rates• High Rate of SVR with the All-Oral Combination of Daclatasvir Plus Sofosbuvir with or without Ribavirin• An Interferon-Free, Ribavirin-Free 12-Week Regimen of Daclatasvir, Asunaprevir, and BMS-791325 Achieved High SVR4 RatesPLUS Meeting Abstract Summaries With Expert Commentary by: Fred Poordad, MDUniversity of San Antonio Health Science CenterSan Antonio, Texas. : Gastroenterology & hepatology.
Chicago
20140521. A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From AASLD 2012: The 63rd Annual Meeting of the American Association for the Study of Liver DiseasesNovember 9-13, 2012 • Boston, MassachusettsSpecial Reporting on:• Timing and Magnitude of Ribavirin Dose Reduction Do Not Impact SVR Rates with Boceprevir Plus Peginterferon α and Ribavirin• A 12-Week Interferon-Free Treatment Regimen with ABT-450/r, ABT-267, ABT-333, and Ribavirin Achieves High SVR12 Rates• High Rate of SVR with the All-Oral Combination of Daclatasvir Plus Sofosbuvir with or without Ribavirin• An Interferon-Free, Ribavirin-Free 12-Week Regimen of Daclatasvir, Asunaprevir, and BMS-791325 Achieved High SVR4 RatesPLUS Meeting Abstract Summaries With Expert Commentary by: Fred Poordad, MDUniversity of San Antonio Health Science CenterSan Antonio, Texas. : Gastroenterology & hepatology.
Harvard
(20140521). A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From AASLD 2012: The 63rd Annual Meeting of the American Association for the Study of Liver DiseasesNovember 9-13, 2012 • Boston, MassachusettsSpecial Reporting on:• Timing and Magnitude of Ribavirin Dose Reduction Do Not Impact SVR Rates with Boceprevir Plus Peginterferon α and Ribavirin• A 12-Week Interferon-Free Treatment Regimen with ABT-450/r, ABT-267, ABT-333, and Ribavirin Achieves High SVR12 Rates• High Rate of SVR with the All-Oral Combination of Daclatasvir Plus Sofosbuvir with or without Ribavirin• An Interferon-Free, Ribavirin-Free 12-Week Regimen of Daclatasvir, Asunaprevir, and BMS-791325 Achieved High SVR4 RatesPLUS Meeting Abstract Summaries With Expert Commentary by: Fred Poordad, MDUniversity of San Antonio Health Science CenterSan Antonio, Texas. : Gastroenterology & hepatology.
MLA
A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From AASLD 2012: The 63rd Annual Meeting of the American Association for the Study of Liver DiseasesNovember 9-13, 2012 • Boston, MassachusettsSpecial Reporting on:• Timing and Magnitude of Ribavirin Dose Reduction Do Not Impact SVR Rates with Boceprevir Plus Peginterferon α and Ribavirin• A 12-Week Interferon-Free Treatment Regimen with ABT-450/r, ABT-267, ABT-333, and Ribavirin Achieves High SVR12 Rates• High Rate of SVR with the All-Oral Combination of Daclatasvir Plus Sofosbuvir with or without Ribavirin• An Interferon-Free, Ribavirin-Free 12-Week Regimen of Daclatasvir, Asunaprevir, and BMS-791325 Achieved High SVR4 RatesPLUS Meeting Abstract Summaries With Expert Commentary by: Fred Poordad, MDUniversity of San Antonio Health Science CenterSan Antonio, Texas. : Gastroenterology & hepatology. 20140521.